CLINICAL TRIALS PROFILE FOR AGENERASE

All Clinical Trials for AGENERASE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005017 ↗	Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment	Unknown status	Glaxo Wellcome	Phase 4	1969-12-31	The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV).
NCT00006591 ↗	Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment	Unknown status	Gathe, Joseph, M.D.	N/A	1969-12-31	The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	National Institute of Mental Health (NIMH)	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	National Institutes of Health (NIH)	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
NCT00624195 ↗	Clinical Trial of CNS-targeted HAART (CIT2)	Completed	University of California, San Diego	Phase 2/Phase 3	2007-03-01	CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.

Clinical Trial Conditions for AGENERASE

Condition Name

Condition Name for AGENERASE
Intervention	Trials
HIV Infections	3

Condition MeSH

Condition MeSH for AGENERASE
Intervention	Trials
HIV Infections	3

Clinical Trial Locations for AGENERASE

Trials by Country

Trials by Country for AGENERASE
Location	Trials
United States	6

Trials by US State

Trials by US State for AGENERASE
Location	Trials
Maryland	1
California	1
Texas	1
North Carolina	1
New York	1

Clinical Trial Progress for AGENERASE

Clinical Trial Phase

Clinical Trial Phase for AGENERASE
Clinical Trial Phase	Trials
Phase 4	1
Phase 2/Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for AGENERASE
Clinical Trial Phase	Trials
Unknown status	2
Completed	1

Clinical Trial Sponsors for AGENERASE

Sponsor Name

Sponsor Name for AGENERASE
Sponsor	Trials
Glaxo Wellcome	1
Gathe, Joseph, M.D.	1
National Institute of Mental Health (NIMH)	1

Sponsor Type

Sponsor Type for AGENERASE
Sponsor	Trials
Other	2
NIH	2
Industry	1

AGENERASE Market Analysis and Financial Projection

Last updated: February 5, 2026

What is the current status of clinical trials for AGENERASE?

AGENERASE (amprenavir) has completed its formal clinical trial phases. It was approved by the U.S. Food and Drug Administration (FDA) in 1999 for the treatment of HIV-1 infection. Post-approval, the drug underwent additional studies focusing on long-term safety, drug-drug interactions, and efficacy in diverse patient populations. No active clinical trial listings for AGENERASE exist on ClinicalTrials.gov as of January 2023, indicating the drug is not currently under investigation for new indications or formulations. Its usage has declined primarily due to the development of newer protease inhibitors with better tolerability and dosing convenience.

How has market demand evolved for AGENERASE?

Market demand for AGENERASE has significantly decreased over the last decade. The decline results from multiple factors:

• Introduction of newer protease inhibitors (e.g., darunavir, atazanavir) that demonstrate improved safety profiles and simplified dosing.
• Shift toward integrase strand transfer inhibitors (INSTIs), which show superior efficacy with fewer side effects.
• Patent expiration and the availability of generic versions, reducing price and limiting revenue for the original branded drug.
• Changes in treatment guidelines favoring drugs with better tolerability and adherence profiles, leading to diminished prescribing of AGENERASE.

In 2011, global sales peaked at approximately $150 million. By 2022, sales had fallen below $10 million, with most revenue derived from legacy markets and limited use in developing regions.

What are the key market segments and geographic trends?

Market segments:

• HIV treatment centers in North America, Europe, and select Asia-Pacific countries.
• Generic drug distributors and pharmacy benefit managers (PBMs).
• Limited use in pediatric populations due to formulation issues.

Geographic trends:

• North America accounts for roughly 60% of remaining sales.
• Europe contributes about 20%, primarily through legacy supply.
• Asia-Pacific markets are experiencing marginal demand growth due to expanding HIV treatment programs but predominantly favor newer agents.

What are the competitive considerations and pipeline prospects?

AGENERASE faces stiff competition:

• Generics: Several companies produce generic amprenavir, leading to price erosion.
• Alternative drugs: Drugs like darunavir and atazanavir offer improved tolerability.
• Newer classes: INSTIs and protease inhibitors with once-daily dosing regimes and reduced adverse effects.

No clinical pipeline or new formulation development efforts are publicly reported. The product is considered a legacy asset, with manufacturer Merck & Co. having largely exited the market.

What are the future projections and market outlook?

Given the current landscape:

• Market trajectory: Continued decline expected through 2025 due to ongoing competition and therapy shift.
• Revenue forecast: Likely to stabilize near current minimal levels before disappearing from most markets.
• Strategic considerations: Companies may retain rights for niche markets or license to generic manufacturers for low-cost access but will not invest in growth initiatives.

External factors impacting the outlook include global HIV treatment access programs and patent litigation status. Price reductions and licensing may prolong some usage in low-income regions.

Key takeaways

• AGENERASE is a legacy HIV drug with no active clinical trials.
• Market demand has declined sharply, with sales focused on legacy markets.
• Competition from generics and newer drug classes has driven its obsolescence.
• No pipeline or new formulation developments are underway.
• Future sales are expected to diminish, with minimal role in global HIV treatment.

FAQs

1. Is AGENERASE still FDA-approved for HIV treatment?
Yes. It received FDA approval in 1999 and remains approved. No new indications or formulations have been approved since.

2. Can AGENERASE be used for anything other than HIV now?
No. Its use is limited to ongoing legacy treatments or formulary needs where other options are unavailable.

3. What is the main reason for its market decline?
The advent of drugs with better safety, efficacy, and dosing convenience, combined with patent expiration and generic availability.

4. Are there ongoing clinical trials related to amprenavir?
No. The drug's clinical development phase concluded over a decade ago, with no active investigations reported.

5. Is there a commercial opportunity for AGENERASE?
Limited. Its role is confined to legacy markets, and current trends favor newer HIV medications.

---

References:

[1] ClinicalTrials.gov. Amprenavir studies and status.
[2] IMS Health. HIV drug sales data, 2011-2022.
[3] U.S. Food and Drug Administration. AGENERASE approval details, 1999.
[4] MarketsandMarkets. HIV therapeutics market analysis, 2022.
[5] Merck & Co. Company reports and pipeline overview, 2023.